Edgar Filing: CMEA VENTURES LIFE SCIENCES 2000 LP

Ownership Submission

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0287

Expires:

January 31, 2005

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

CMEA VENTURES LIFE SCIENCES 2000 LP

2. Issuer Name and Ticker or Trading Symbol
CODEXIS INC [CDXS]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

_____ Director	__X__ 10% Owner
_____ Officer (give title below)	_____ Other (specify below)

(Last)

(First)

(Middle)

ONE EMBARCADERO CENTER, SUITE 3250

3. Date of Earliest Transaction (Month/Day/Year)
04/27/2010

(Street)

SAN FRANCISCO, CA 94111

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/27/2010		C		93,727 ⁽¹⁾ ⁽²⁾	A	⁽²⁾	93,727	I	See Footnote ⁽³⁾
Common Stock	04/27/2010		C		62,815 ⁽¹⁾ ⁽⁴⁾	A	⁽⁴⁾	156,542	I	See Footnote ⁽³⁾
Common Stock	04/27/2010		C		24,525 ⁽¹⁾ ⁽⁵⁾	A	⁽⁵⁾	181,067	I	See Footnote ⁽³⁾
Common Stock	04/27/2010		C		1,418,477 ⁽¹⁾ ⁽²⁾	A	⁽²⁾	1,418,477	I	See Footnote ⁽⁶⁾
Common Stock	04/27/2010		C		950,638 ⁽¹⁾ ⁽⁴⁾	A	⁽⁴⁾	2,369,115	I	See Footnote ⁽⁶⁾
Common Stock	04/27/2010		C		371,043 ⁽¹⁾ ⁽⁵⁾	A	⁽⁵⁾	2,740,158	I	See Footnote ⁽⁶⁾

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code
(Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date
(Month/Day/Year)

7. Title and Amount of Underlying Securities
(Instr. 3 and 4)

8. Price of Derivative Security
(Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)

11. Nature of Indirect Beneficial Ownership
(Instr. 4)

Code

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Series B Preferred Stock

⁽²⁾

04/27/2010

93,727 ⁽¹⁾ ⁽²⁾

⁽²⁾

⁽⁷⁾

Common Stock

93,727 ⁽¹⁾ ⁽²⁾

$ 0

See Footnote ⁽³⁾

Series D Preferred Stock

⁽⁴⁾

04/27/2010

62,815 ⁽¹⁾ ⁽⁴⁾

⁽⁴⁾

⁽⁷⁾

Common Stock

62,815 ⁽¹⁾ ⁽⁴⁾

$ 0

See Footnote ⁽³⁾

Series E Preferred Stock

⁽⁵⁾

04/27/2010

24,525 ⁽¹⁾ ⁽⁵⁾

⁽⁵⁾

⁽⁷⁾

Common Stock

24,525 ⁽¹⁾ ⁽⁵⁾

$ 0

See Footnote ⁽³⁾

Series B Preferred Stock

⁽²⁾

04/27/2010

1,418,477 ⁽¹⁾ ⁽²⁾

⁽²⁾

⁽⁷⁾

Common Stock

1,418,477 ⁽¹⁾ ⁽²⁾

$ 0

See Footnote ⁽⁶⁾

Series D Preferred Stock

⁽⁴⁾

04/27/2010

950,638 ⁽¹⁾ ⁽⁴⁾

⁽⁴⁾

⁽⁷⁾

Common Stock

950,638 ⁽¹⁾ ⁽⁴⁾

$ 0

See Footnote ⁽⁶⁾

Series E Preferred Stock

⁽⁵⁾

04/27/2010

371,043 ⁽¹⁾ ⁽⁵⁾

⁽⁵⁾

⁽⁷⁾

Common Stock

371,043 ⁽¹⁾ ⁽⁵⁾

$ 0

See Footnote ⁽⁶⁾

Warrant to Purchase Series D Preferred Stock

$ 5.96 ⁽¹⁾ ⁽⁸⁾

04/27/2010

5,730 ⁽¹⁾ ⁽⁸⁾

⁽⁹⁾

05/25/2013

Series D Preferred Stock

5,730 ⁽¹⁾ ⁽⁸⁾

$ 0

See Footnote ⁽³⁾

Warrant to Purchase Common Stock

$ 5.96 ⁽¹⁾ ⁽⁸⁾

04/27/2010

5,730 ⁽¹⁾ ⁽⁸⁾

⁽⁹⁾

05/25/2013

Common Stock

5,730 ⁽¹⁾ ⁽⁸⁾

$ 0

5,730 ⁽¹⁾

See Footnote ⁽³⁾

Warrant to Purchase Series D Preferred Stock

$ 5.96 ⁽¹⁾ ⁽⁸⁾

04/27/2010

86,718 ⁽¹⁾ ⁽⁸⁾

⁽⁹⁾

05/25/2013

Series D Preferred Stock

86,718 ⁽¹⁾ ⁽⁸⁾

$ 0

See Footnote ⁽⁶⁾

Warrant to Purchase Common Stock

$ 5.96 ⁽¹⁾ ⁽⁸⁾

04/27/2010

86,718 ⁽¹⁾ ⁽⁸⁾

⁽⁹⁾

05/25/2013

Common Stock

86,718 ⁽¹⁾ ⁽⁸⁾

$ 0

86,718 ⁽¹⁾

See Footnote ⁽⁶⁾

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
CMEA VENTURES LIFE SCIENCES 2000 LP ONE EMBARCADERO CENTER, SUITE 3250 SAN FRANCISCO, CA 94111		X
CMEA Ventures Life Sciences 2000, Civil Law Partnership ONE EMBARCADERO CENTER, SUITE 3250 SAN FRANCISCO, CA 94111		X
CMEA Ventures LS Management 2000, L.P. ONE EMBARCADERO CENTER, SUITE 3250 SAN FRANCISCO, CA 94111		X
Collier David J ONE EMBARCADERO CENTER, SUITE 3250 SAN FRANCISCO, CA 94111		X
Handelsman Karl D. ONE EMBARCADERO CENTER, SUITE 3250 SAN FRANCISCO, CA 94111		X

Signatures

/s/ Thomas R. Baruch, General Partner of CMEA Ventures LS Management 2000, L.P. for CMEA Ventures Life Sciences 2000, L.P. as its General Partner		04/29/2010
^**Signature of Reporting Person		Date
/s/ Thomas R. Baruch, General Partner of CMEA Ventures LS Management 2000, L.P. for CMEA Ventures Life Sciences 2000, Civil Law Partnership as its managing limited partner		04/29/2010
^**Signature of Reporting Person		Date
/s/ Thomas R. Baruch, General Partner of CMEA Ventures LS Management 2000, L.P.		04/29/2010
^**Signature of Reporting Person		Date
/s/ David Collier		04/29/2010
^**Signature of Reporting Person		Date
/s/ Karl Handelsman		04/29/2010
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Reflects a 2-for-3 reverse stock split of the Issuer's outstanding securities effected immediately prior to the effectiveness of the Issuer's S-1 Registration Statement (Commission File No. 333-164044).
(2)	Each share of Series B Preferred Stock automatically converted into Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering.
(3)	Held by CMEA Ventures Life Sciences 2000, Civil Law Partnership. Thomas R. Baruch, a member of the Issuer's board of directors, David Collier and Karl Handelsman are general partners of CMEA Ventures LS Management 2000, L.P., the managing limited partner of CMEA Ventures Life Sciences 2000, Civil Law Partnership, and, as such, have voting and investment power over the securities held by CMEA Ventures Life Sciences 2000, Civil Law Partnership. Each of the Reporting Persons disclaims beneficial ownership of the securities reported in this Form 4 except to the extent of any pecuniary interest therein.
(4)	Each share of Series D Preferred Stock automatically converted into Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering.
(5)	As previously reported on the Form 3 dated April 21, 2010, due to the antidilution provisions of the Issuer's certificate of incorporation that apply to the Series E Preferred Stock, each share of Series E Preferred Stock automatically converted into Common Stock on a 1.008702-for-1 basis upon the closing of the Issuer's initial public offering. Number of shares reported includes the additional 211 shares and 3,200 shares of Common Stock that was issued to CMEA Ventures Life Sciences 2000, Civil Law Partnership and CMEA Ventures Life Sciences 2000, L.P., respectively, upon such conversion as a result of such antidilution adjustment.
(6)	Held by CMEA Ventures Life Sciences 2000, L.P. Thomas R. Baruch, a member of the Issuer's board of directors, David Collier and Karl Handelsman are general partners of CMEA Ventures LS Management 2000, L.P., the general partner of CMEA Ventures Life Sciences 2000, L.P., and, as such, have voting and investment power over the securities held by CMEA Ventures Life Sciences 2000, L.P. Each of the Reporting Persons disclaims beneficial ownership of the securities reported in this Form 4 except to the extent of any pecuniary interest therein.
(7)	The expiration date is not relevant to the conversion of these securities.
(8)	Upon completion of the Issuer's initial public offering, the warrant to purchase shares of Series D Preferred Stock automatically converted into a warrant to purchase an equal number of shares of the Issuer's Common Stock. Disposition of Warrant to Series D Preferred Stock and acquisition of Warrant to Purchase Common Stock listed solely for the purpose of reporting such conversion of the shares underlying the security.
(9)	This warrant is immediately exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.